Austerity in Portugal drops drug bill 21%, drives parallel exports, hospital debt
This article was originally published in Scrip
Market conditions in Portugal are continuing to deteriorate as cost cutting has fuelled parallel exports and hospitals owe companies increasingly more money, APIFARMA, the local R&D-based pharmaceutical industry association, has warned.
You may also be interested in...
An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.